EC
CHRS icon

EntryPoint Capital’s Coherus Oncology CHRS Stock Holding History

EntryPoint Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1K Buy
+24,377
New +$39.8K 0.01% 768
2024
Q2 		– Sell
-41,879
Closed -$100K – 1456
2024
Q1 		$100K Buy
+41,879
New +$103K 0.09% 420

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

EntryPoint Capital's CHRS Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Coherus Oncology (CHRS) in Q2 2026: 24,377 shares worth $34.1K. The stake represents 0.01% of the portfolio and ranks #768 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in CHRS as recently as Q1 2024.

EntryPoint Capital first reported a position in CHRS in Q1 2024 and has held it in 2 quarters since. The position peaked at $100K in Q1 2024. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • EntryPoint Capital held 24,377 shares of Coherus Oncology worth $34.1K as of Q2 2026.
  • Coherus Oncology was a new EntryPoint Capital position in Q2 2026.
  • Coherus Oncology made up 0.01% of EntryPoint Capital's portfolio in Q2 2026, its #768 holding.
  • EntryPoint Capital first reported a position in Coherus Oncology in Q1 2024 and has held it in 2 quarters since.
  • EntryPoint Capital's Coherus Oncology position peaked at $100K in Q1 2024.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.